Angiotensin II
Use
The renin-angiotensin aldosterone hormonal cascade that regulates blood pressure and water (fluid) balance begins with the biosynthesis of renin by the juxtaglomerular cells that line the afferent (and occasionally efferent) arteriole of the renal glomerulus.1,2 A drop in blood pressure decreases the perfusion of the juxtaglomerular apparatus, resulting in the release of the enzyme renin. Renin proceeds to cleave angiotensinogen to produce angiotensin I. Angiotensin I is in turn converted to angiotensin II by angiotensin-converting enzyme (ACE), which is found mainly in lung capillaries. Angiotensin II is the major bioactive product of the renin-angiotensin system, binding to receptors on intraglomerular mesangial cells, causing these cells to contract along with the blood vessels surrounding them and causing the release of aldosterone from the adrenal cortex. Angiotensin II has multifaceted effects on aldosterone secretion, vasoconstriction, sodium reabsorption, and fluid volume, all of which serve to raise blood pressure. Laboratory studies with cultured cardiomyocytes have implicated angiotensin as a direct cause of left ventricular hypertrophy associated with hypertension. Angiotensin II also inhibits renin release by the kidney via a feedback mechanism.
Special Instructions
Contact the LabCorp supply department for collection kit. Ensure that the patient has not received any radioactive substances 24 hours prior to the test and that they are fasting. Submit separate frozen specimens for each requested test to avoid turnaround delays.
Limitations
Results from this test are for research purposes as per the manufacturer's assay. The test's performance characteristics have not been thoroughly established, therefore results should not be used alone for diagnosis without confirmation via another medically established diagnostic procedure.
Methodology
Immunoassay (RIA)
Biomarkers
LOINC Codes
- 1860-6
- 1860-6
Result Turnaround Time
4-14 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL
Minimum Volume
1.5 mL
Container
Lavender-top (EDTA) tube with Trasylol®
Collection Instructions
Trasylol® kits can be ordered via the PeopleSoft system (LabCorp N° 33328). Collect whole blood using a chilled 6-mL lavender-top (EDTA) tube. Mix by inverting the tube several times. Add 0.25 mL Trasylol® using a sterile Beral pipette, mix by inversion, then centrifuge to separate plasma. Transfer plasma to the brown screw-cap tubes, label as 'Trasylol® Added,' and freeze.
Patient Preparation
Patient should not receive radioactive substances for 24 hours prior; must be fasting.
Storage Instructions
Freeze.
Causes for Rejection
Sample not collected with Trasylol®; sample not submitted in the appropriately labeled tube; gross hemolysis; recent radioisotope administration; specimen not frozen; inappropriate tube or specimen type (serum, sodium citrate, or heparinized plasma); lipemia.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 hour |
| Refrigerated | 1 hour |
| Frozen | 14 days |
